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Objectives: Escherichia coli ST131 is a globally disseminated MDR clone originally identified due to its association
with the blaCTX-M-15 gene encoding an ESBL. It is thus assumed that blaCTX-M-15 is the major determinant for
resistance to b-lactam antibiotics in this clone. The complete sequence of EC958, a reference strain for E. coli
ST131, revealed that it contains a chromosomally located blaCMY-23 gene with an upstream ISEcp1 element as
well as several additional plasmid-encoded b-lactamase genes. Here, we examined the genetic context of the
blaCMY-23 element in EC958 and other E. coli ST131 strains and investigated the contribution of blaCMY-23 to EC958
resistance to a range of b-lactam antibiotics.
Methods: The genetic context of blaCMY-23 and its associated mobile elements was determined by PCR and
sequencing. Antibiotic susceptibility testing was performed using Etests. The activity of the blaCMY-23 promoter
was assessed using lacZ reporter assays. Mutations were generated using l-Red-recombination.
Results: The genetic structure of the ISEcp1-IS5-blaCMY-23 mobile element was determined and localized within
the betU gene on the chromosome of EC958 and five other E. coli ST131 strains. The transcription of blaCMY-23,
driven by a previously defined promoter within ISEcp1, was significantly higher than other b-lactamase genes
and could be induced by cefotaxime. Deletion of the blaCMY-23 gene resulted in enhanced susceptibility to
cefoxitin, cefotaxime and ceftazidime.
Conclusions: This is the first known report to demonstrate the chromosomal location of blaCMY-23 in E. coli ST131.
In EC958, CMY-23 plays a major role in resistance to third-generation cephalosporins and cephamycins.
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Introduction
Escherichia coli ST131 is a globally disseminated MDR clone originally
identified due to its close association with the spread of the
blaCTX-M-15 ESBL gene.
1–3 Two studies have recently reported the glo-
bal epidemiology of E. coli ST131 using WGS, and revealed the
blaCTX-M-15 allele is highly prevalent within a fluoroquinolone-resistant
FimH30 (H30) ST131 sublineage (referred to as clade C24 or H30-Rx5).
We have characterized and completely sequenced the reference
ST131 strain EC958.6 E. coli EC958 is a urinary tract infection
(UTI)-derived fluoroquinolone-resistant, fimH30 E. coli ST131 strain.7
The strain is a representative member of the UK epidemic strain A,
one of the major pathogenic lineages causing UTI across the UK,3
and belongs to the recently defined phylogenetic C2 lineage of
ST131.4 EC958 contains a large multidrug resistance plasmid
(pEC958; HG941719) that harbours a copy of blaCTX-M-15 gene. The
blaCTX-M-15 gene has always been seen with an upstream ISEcp1
insertion element.8 ISEcp1 contains a well-described outward-facing
promoter that drives the transcription of the downstream blaCTX-M-15
gene,9 and this transposition unit has been identified on multiple
plasmids characterized from ST131 strains.10 Several different inser-
tions of IS26 in the region upstream of blaCTX-M-15 have been reported,
including the insertion at 24 bp upstream of the right inverted repeat
(IRR) of ISEcp1, which results in reduced resistance to cephalospor-
ins.10 This particular insertion was first identified in UK epidemic
strain A isolates and was also found on plasmid pEC958 from the
E. coli ST131 strain EC958.
In addition to the production of ESBLs, resistance to third-
generation cephalosporins can also be mediated by chromosomal
and plasmid-encoded AmpC (or class C) b-lactamases.11 The
plasmid-encoded blaCMY-1 gene and its variants are related to
chromosomal AmpC enzymes from Aeromonas spp., while
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blaCMY-2 and its variants are related to AmpC b-lactamases from
Citrobacter freundii.11 blaCMY-2 gene is the most frequently
reported plasmid-mediated AmpC b-lactamase worldwide; it
confers resistance to cephamycins (cefoxitin and cefotetan) and
oxyimino-cephalosporins (cefotaxime and ceftazidime) and is
poorly inhibited by b-lactamase inhibitors, including clavulanate,
sulbactam and tazobactam.12 Several studies have reported the
identification of blaCMY-2 in E. coli ST131.
13,14 In addition, a variant
of blaCMY-2, named blaCMY-23, has been identified in several E. coli
ST131 isolates belonging to the UK epidemic E. coli strain A.15 The
blaCMY-2 and blaCMY-23 genes differ by a single nucleotide, which
results in a Glu239Gly amino acid substitution in CMY-23.
A blaCMY-23 gene accompanied by an upstream ISEcp1 insertion
element was found inserted in the chromosome of EC958. This led
us to hypothesize that CMY-23, instead of CTX-M-15, is the
b-lactamase responsible for cephalosporin resistance in EC958.
Here, we investigated the contribution of blaCMY-23 to EC958 resist-
ance to a range of b-lactam antibiotics, and demonstrated that it
is the primary mediator of resistance to third-generation cepha-
losporins and cephamycins.
Materials and methods
Bacterial strains and growth conditions
The strains used in this study are listed in Table S1 (available as
Supplementary data at JAC Online). All E. coli strains were routinely cul-
tured at 378C on solid or in liquid Lysogeny Broth (LB) medium supplemen-
ted with an appropriate antibiotic: chloramphenicol (30 mg/L), gentamicin
(20 mg/L) or ampicillin (100 mg/L).
Antimicrobial susceptibility testing
The MICs of b-lactam antibiotics were determined by Etest (bioMérieux
Australia) on Mueller–Hinton agar at 378C using EUCAST breakpoints
(http://www.eucast.org/clinical breakpoints/).
Molecular methods
Genomic DNA preparation and DNA sequencing were performed as
described previously.16 Oligonucleotides used in this study are listed in
Table S2. Plasmids pQF50::ISEcp1 and pQF50::IS5+ISEcp1 were created by
PCR amplification of the fragments indicated in Table S1 and cloned into
pQF50 via BamHI–HindIII digestion. The resulting plasmids were electropo-
rated into E. coli TOP10. Mutants containing deletions in the blaCMY-23 gene
and IS5 were constructed by l-Red-mediated recombination as previously
described.7 b-Galactosidase assays were performed as previously
described.16
Results and discussion
The blaCMY-23 gene is located on the chromosome
of E. coli EC958
E. coli EC958 contains a chromosomally encoded blaCMY-23 gene
(EC958_4781). Closer inspection of its genomic context suggests
an insertion event of a 4277 bp mobile element (nucleotides
4937 433–4941 709, including ISEcp1, IS5 and blaCMY-23) into
the betU gene (encodes a betaine uptake system) within the
GI-leuX genomic island, creating 5 bp direct repeats (DRs) of TATAT
(Figure 1a). This insertion was not found in the E. coli ST131 strain
JJ1886 (CP006784), which harbours two tandem copies of the
GI-leuX island (Figure S1). ISEcp1 is known to mediate the transpos-
ition of its downstream genes using an imperfect IRR (IRR′).17 Indeed,
we identified an IRR′ with the sequence 5′-gtGTAGctcCccGa-3′
(nucleotides matching the ISEcp1 IRR are capitalized) immediately
before the right DR. The IS5 element is located 152 bp before the
end of ISEcp1 (Figure 1b and c) and flanked by a 4 bp DR of TTAA.
This location does not interrupt the ISEcp1 transposase gene and
leaves the promoter region at the end of ISEcp1 intact. It is not
clear whether this IS5 insertion occurred prior to or after the move-
ment of ISEcp1-blaCMY-23 to the chromosome.
Prevalence of ISEcp1-blaCMY-23
The blaCMY-23 gene (DQ438952) was first reported from isolates
within the UK epidemic strain A, which was later shown to be
part of the E. coli ST131 lineage.15 A second blaCMY-23 sequence
has been reported from Salmonella enterica serovar Senftenberg
(DQ463751). However, neither of these entries includes informa-
tion about the genomic context nor location of the blaCMY-23 gene.
Analysis of a global collection of previously sequenced ST131
strains4 identified five clade C2 strains (S30EC, accession number
ERR161246; S39EC, accession number ERR161248; S43EC, acces-
sion number ERR161249; S47EC, accession number ERR161250;
and S53EC, accession number ERR161251) that possess the
blaCMY-23 gene. Further PCR and sequencing of S30EC, S39EC and
S43EC confirmed that they contain an identical ISEcp1-IS5-
blaCMY-23 sequence inserted at the same location on the chromo-
some as in EC958 (Figure 1b). Of note, EC958 and these five strains
were all isolated from the same hospital in the UK (from 2004 to
2007) where the first blaCMY-23 positive strain was reported.
15
We also identified one strain (S79EC, accession number
ERR161305) from the ST131 clade A phylogeny that contained the
blaCMY-2 gene within a transposition unit identical to that found in
IncI1 plasmids pSTM709 (HG428759) and pCVM29188_101
(CP001121). This unit lacks IS5, has a longer region downstream
of ISEcp1 (2253 bp compared with 1422 bp) and based on its flank-
ing genes may be located on a plasmid in S79EC (Figure 1b).
The blaCMY-23 gene is the major contributor to EC958
resistance to third-generation cephalosporins
EC958 harbours several genes that could contribute to its
resistance to b-lactam antibiotics, including blaTEM-1, blaOXA-1,
blaCTX-M-15, blaCMY-23 and the chromosomal ampC gene. To specific-
ally demonstrate the contribution of blaCMY-23 to EC958 resistance,
we mutated the blaCMY-23 gene using l-Red-mediated homologous
recombination. The resultant strain, designated EC958DblaCMY-23,
was then tested in parallel with WT EC958 against a panel of
b-lactam antibiotics. Despite the presence of pEC958 (which har-
bours blaTEM-1, blaOXA-1 and blaCTX-M-15), EC958DblaCMY-23 displayed
significantly enhanced susceptibility to cefoxitin, cefotaxime and
ceftazidime (8–16-fold reduction in MIC; Table 1) compared with
WT EC958. Taken together, our data confirm that the blaCMY-23
gene is the main determinant that mediates resistance to second-
and third-generation cephalosporins in EC958.
blaCMY-23 expression is induced by cefotaxime, but not
affected by IS5
We used qRT –PCR to evaluate the transcription of the five
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is the most strongly transcribed b-lactamase gene in EC958
(8-fold higher than the reference gene recA; Figure S2). In contrast
blaCTX-M-15 is transcribed weakest (12-fold lower than recA). These
data are consistent with the mutant data reported above, and in
accordance with previous publications that show ISEcp1 contains
a functional promoter that drives the transcription of downstream
genes including CMY variants.9,18
To investigate the activity of the blaCMY-23 promoter in EC958,
we cloned the region corresponding to the end of ISEcp1 in
front of the promoterless lacZ gene in plasmid pQF50 to generate
plasmid pQF50::ISEcp1. A 2-fold increase in b-galactosidase activ-
ity was observed for E. coli TOP10 harbouring pQF50::ISEcp1
grown in LB medium containing cefotaxime compared with LB




Figure 1. The chromosomal location of blaCMY-23 in EC958 and other E. coli ST131 strains. (a) The insertion of ISEcp1 (purple), IS5 (green) and blaCMY-23
(red) into the betU gene. The sequences of DRs and inverted repeats supporting putative transposition events are shown. (b) Sequence comparisons
showing the genomic context of blaCMY-23 on the chromosome of ST131 strains and the closely related blaCMY-2 on IncI1 plasmids. The grey shadow
connecting different strains indicates 100% similarity except for one single nucleotide change in blaCMY-2 resulting in an E to G amino acid change in
CMY-23 (indicated by arrow heads with the respective amino acid code). The boxed sequence is shown in full in panel (c). (c) The sequence of the blaCMY-23
promoter region showing the 210 and 235 promoter consensus sites provided by ISEcp1 (underlined within the purple region), as well as the
C. freundii-derived partial AmpR binding site and associated promoter sequence. (d) b-Galactosidase assays showing the activity of the ISEcp1
promoter and its induction in the presence of cefotaxime. b-Galactosidase activity is expressed as Miller units. CTX, cefotaxime; IRL, left inverted
repeat. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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activity was detected in the vector control strain grown under the
same conditions.
IS5 has been shown to alter transcription by enhancing the activity
of a promoter downstream of its site of insertion.19,20 Thus, we inves-
tigated whether the IS5 element located within ISEcp1 affects expres-
sion of the blaCMY-23 gene using two complementary approaches. First,
we cloned the ISEcp1 promoter region together with the upstream IS5
in front of the promoterless lacZ gene in plasmid pQF50 to generate
plasmid pQF50::IS5+ISEcp1 and showed that there was no difference
in the b-galactosidase activity between TOP10(pQF50::IS5+ISEcp1)
and TOP10(pQF50::ISEcp1) (Figure 1d). Second, we deleted the IS5
element using l-Red-mediated homologous recombination. The
resultant strain, designated EC958DIS5, did not show any difference
in antibiotic resistance profile from that of WT EC958 (Table 1).
These results demonstrate that the blaCMY-23 promoter provided by
ISEcp1 is functional and can be induced by cefotaxime.
Conclusions
blaCTX-M-15 is considered to be the main determinant for resistance
to third-generation cephalosporins in E. coli ST131. Here, we
showed that in EC958, which contains a plasmid-located
blaCTX-M-15 gene, cephalosporin resistance is conferred by a
chromosomal blaCMY-23 gene that encodes an AmpC type
b-lactamase. We also showed that the blaCMY-23 in EC958 is
strongly transcribed from a promoter located within ISEcp1 that
can be induced by cefotaxime.
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Table 1. Antimicrobial susceptibility (expressed as MIC in mg/L) of EC958
WT and mutant strains
Antibiotic EC958 EC958DblaCMY-23 EC958DIS5
Ampicillin ≥256 (R) ≥256 (R) ≥256 (R)
Amoxicillin/clavulanic acid 24 (R) 12 (R) 16 (R)
Piperacillin ≥256 (R) ≥256 (R) ≥256 (R)
Piperacillin/tazobactam 16 (I) 12 (I) 16 (I)
Cefoxitin 48 (NA) 4 (NA) 48 (NA)
Cefotaxime 12 (R) 1.5 (I) 12 (R)
Ceftazidime 16 (R) 1 (S) 16 (R)
Cefpirome 3 (NA) 1 (NA) 3 (NA)
Aztreonam 2 (I) 1 (S) 2 (I)
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